Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 05 - 13 save search
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells
Published: 2021-05-13 (Crawled : 21:00) - affimed.com
AFMD | $4.91 -8.22% -8.96% 65K
|
Health Technology
|
| O: -0.56%
H: 6.24%
C: -0.11%
potential cancer research preclinical pre-clinical
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
Published: 2021-05-13 (Crawled : 13:15) - biospace.com/
MRUS | $41.96 2.79% 2.72% 740K
|
Health Technology
|
| O: 0.49%
H: 2.72%
C: -1.83%
israel phase 1 collaboration cancer announces collaboration trial phase 3 phase 2
Aspira Women’s Health to Reveal 3rd Generation Ovarian Cancer Risk Assessment Technology at ASCO 2021
Published: 2021-05-13 (Crawled : 12:15) - vermillion.com
AWH | $3.35 -1.18% -1.19% 4.5K
|
Health Technology
|
| O: 1.67%
H: 9.47%
C: -0.21%
risk women cancer technology ovarian cancer health
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Published: 2021-05-13 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.14%
H: 1.41%
C: 1.03%
risk cancer phase 3 breast cancer trial
Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
Published: 2021-05-13 (Crawled : 11:00) - investor.alkermes.com
ALKS | $24.66 1.65% 1.62% 1.7M
|
Health Technology
|
| O: 0.13%
H: 0.85%
C: -1.02%
cancer program
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
Published: 2021-05-13 (Crawled : 01:00) - prnewswire.com
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: 0.34%
H: 6.54%
C: 4.96%
china cancer trial approval
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.